These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 6382528

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
    Walther PJ.
    Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.
    Sternberg CN, Yagoda A, Scher HI, Whitmore WF, Herr HW, Morse MJ, Sogani PC, Watson RC, Hollander PS, Fair WR.
    Prog Clin Biol Res; 1988 Nov; 260():481-5. PubMed ID: 3283768
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adjuvant chemotherapy for non-organ confined bladder transitional cell carcinoma.
    Abi-Aad AS.
    Acta Urol Belg; 1996 May; 64(2):35-7. PubMed ID: 8701808
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
    Balbay MD, Ozen H, Uluçay S, Sahin A, Ergen A, Koçal C, Remzi D.
    Int Urol Nephrol; 1993 May; 25(4):351-7. PubMed ID: 8276565
    [Abstract] [Full Text] [Related]

  • 9. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N.
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [Abstract] [Full Text] [Related]

  • 10. Possible alternative treatment for advanced transitional cell carcinoma of the urothelium (N+ and/or M+) in 1988.
    Perrin P, Mouriquand P, Monsallier M, Devonec M.
    Prog Clin Biol Res; 1989 Jun; 303():617-9. PubMed ID: 2780666
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience.
    Fair WR, Scher H, Herr H, Morse M, Sogani P, Bosi G, Dershaw D, Reuter V, Curley T.
    Semin Urol; 1990 Aug; 8(3):190-6. PubMed ID: 2399387
    [No Abstract] [Full Text] [Related]

  • 14. [Systemic chemotherapy in advanced bladder cancer. New aspects].
    Jakse G.
    Wien Klin Wochenschr; 1987 Jan 23; 99(2):54-7. PubMed ID: 3564487
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.
    Jpn J Clin Oncol; 1993 Oct 23; 23(5):291-8. PubMed ID: 7693990
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Chemotherapy of urothelial tract cancer: Memorial Sloan-Kettering Cancer Center experience.
    Yagoda A.
    Important Adv Oncol; 1988 Oct 23; ():143-59. PubMed ID: 3042602
    [No Abstract] [Full Text] [Related]

  • 20. [Characteristic and effective usage of adriamycin].
    Horiuchi K, Akimoto M.
    Gan To Kagaku Ryoho; 1996 Dec 23; 23(14):1916-9. PubMed ID: 8978797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.